Format

Send to

Choose Destination
Clin Appl Thromb Hemost. 2017 Nov;23(8):1036-1041. doi: 10.1177/1076029616669786. Epub 2016 Sep 21.

Bridge Therapy Outcomes in Patients With Mechanical Heart Valves.

Author information

1
1 Pharmacy Department, Kaiser Permanente Colorado, Aurora, CO, USA.
2
2 Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.
3
3 Clinical Pharmacy Department, Veterans Administration, Colorado Springs, CO, USA.
4
4 Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, USA.
5
5 Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Abstract

BACKGROUND:

Bridge therapy is associated with an increased risk of major bleeding in patients with atrial fibrillation and venous thromboembolism (TE) without a corresponding reduction in TE. The benefits of bridge therapy in patients with mechanical heart valve (MHV) prostheses interrupting warfarin for invasive procedures are not well described.

METHODS AND RESULTS:

A retrospective cohort study was conducted at an integrated health-care delivery system. Anticoagulated patients with MHV interrupting warfarin for invasive diagnostic or surgical procedures between January 1, 2006, and March 31, 2012, were identified. Patients were categorized according to exposure to bridge therapy during the periprocedural period and TE risk (low, medium, and high). Outcomes validated via manual chart review included clinically relevant bleeding, TE, and all-cause mortality in the 30 days following the procedure. There were 547 procedures in 355 patients meeting inclusion criteria. Mean cohort age was 65.2 years, and 38% were female. Bridge therapy was utilized in 466 (85.2%) procedures (95.2%, 77.3%, and 65.8% of high, medium, and low TE risk category procedures, respectively). The 30-day rate of clinically relevant bleeding was numerically higher in bridged (5.8%; 95% confidence interval [CI], 3.9%-8.3%) versus not bridged procedures (1.2%; 95% CI, <0.1%-6.7%; P = .102). No TEs or deaths were identified.

CONCLUSION:

The use of bridge therapy is common among patients with MHV and may be associated with increased bleeding risk. Further research is needed to determine whether bridge therapy reduces TE in patients with MHV interrupting warfarin for invasive procedures.

KEYWORDS:

anticoagulants; bleeding; heart valve; surgery; thrombosis

PMID:
27655997
DOI:
10.1177/1076029616669786
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center